Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG002 Injection in HPV16/18-Associated CIN2/3
ChiCTR2500099912Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RG002 in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection, sponsored by Peking Union Medical College Hospital. Primary endpoints: Types, incidence, severity, and relationship of adverse events to RG002 injection, Clinically significant changes in vital signs, physical examination, laboratory tests, and 12-lead ECG and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
RG002
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2500099912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099912.